1
|
Abe T, Kuwahara T. Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. Front Neurol 2021; 12:681369. [PMID: 34194386 PMCID: PMC8236816 DOI: 10.3389/fneur.2021.681369] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 05/20/2021] [Indexed: 01/01/2023] Open
Abstract
Previous genetic studies on hereditary Parkinson's disease (PD) have identified a set of pathogenic gene mutations that have strong impacts on the pathogenicity of PD. In addition, genome-wide association studies (GWAS) targeted to sporadic PD have nominated an increasing number of genetic variants that influence PD susceptibility. Although the clinical and pathological characteristics in hereditary PD are not identical to those in sporadic PD, α-synuclein, and LRRK2 are definitely associated with both types of PD, with LRRK2 mutations being the most frequent cause of autosomal-dominant PD. On the other hand, a significant portion of risk genes identified from GWAS have been associated with lysosomal functions, pointing to a critical role of lysosomes in PD pathogenesis. Experimental studies have suggested that the maintenance or upregulation of lysosomal activity may protect against neuronal dysfunction or degeneration. Here we focus on the roles of representative PD gene products that are implicated in lysosomal pathway, namely LRRK2, VPS35, ATP13A2, and glucocerebrosidase, and provide an overview of their disease-associated functions as well as their cooperative actions in the pathogenesis of PD, based on the evidence from cellular and animal models. We also discuss future perspectives of targeting lysosomal activation as a possible strategy to treat neurodegeneration.
Collapse
Affiliation(s)
- Tetsuro Abe
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Tomoki Kuwahara
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
2
|
Doustar J, Rentsendorj A, Torbati T, Regis GC, Fuchs D, Sheyn J, Mirzaei N, Graham SL, Shah PK, Mastali M, Van Eyk JE, Black KL, Gupta VK, Mirzaei M, Koronyo Y, Koronyo‐Hamaoui M. Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer's disease mouse models. Aging Cell 2020; 19:e13246. [PMID: 33090673 PMCID: PMC7681044 DOI: 10.1111/acel.13246] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 08/14/2020] [Accepted: 09/09/2020] [Indexed: 12/20/2022] Open
Abstract
Despite growing evidence for the characteristic signs of Alzheimer's disease (AD) in the neurosensory retina, our understanding of retina-brain relationships, especially at advanced disease stages and in response to therapy, is lacking. In transgenic models of AD (APPSWE/PS1∆E9; ADtg mice), glatiramer acetate (GA) immunomodulation alleviates disease progression in pre- and early-symptomatic disease stages. Here, we explored the link between retinal and cerebral AD-related biomarkers, including response to GA immunization, in cohorts of old, late-stage ADtg mice. This aged model is considered more clinically relevant to the age-dependent disease. Levels of synaptotoxic amyloid β-protein (Aβ)1-42, angiopathic Aβ1-40, non-amyloidogenic Aβ1-38, and Aβ42/Aβ40 ratios tightly correlated between paired retinas derived from oculus sinister (OS) and oculus dexter (OD) eyes, and between left and right posterior brain hemispheres. We identified lateralization of Aβ burden, with one-side dominance within paired retinal and brain tissues. Importantly, OS and OD retinal Aβ levels correlated with their cerebral counterparts, with stronger contralateral correlations and following GA immunization. Moreover, immunomodulation in old ADtg mice brought about reductions in cerebral vascular and parenchymal Aβ deposits, especially of large, dense-core plaques, and alleviation of microgliosis and astrocytosis. Immunization further enhanced cerebral recruitment of peripheral myeloid cells and synaptic preservation. Mass spectrometry analysis identified new parallels in retino-cerebral AD-related pathology and response to GA immunization, including restoration of homeostatic glutamine synthetase expression. Overall, our results illustrate the viability of immunomodulation-guided CNS repair in old AD model mice, while shedding light onto similar retino-cerebral responses to intervention, providing incentives to explore retinal AD biomarkers.
Collapse
Affiliation(s)
- Jonah Doustar
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Altan Rentsendorj
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Tania Torbati
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
- College of Osteopathic Medicine of the PacificWestern University of Health SciencesPomonaCAUSA
| | - Giovanna C. Regis
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Dieu‐Trang Fuchs
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Julia Sheyn
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Nazanin Mirzaei
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Stuart L. Graham
- Department of Clinical MedicineMacquarie UniversitySydneyNSWAustralia
- Save Sight InstituteSydney UniversitySydneyNSWAustralia
| | - Prediman K. Shah
- Oppenheimer Atherosclerosis Research CenterCedars‐Sinai Heart InstituteLos AngelesCAUSA
| | - Mitra Mastali
- Department of Biomedical SciencesCedars‐Sinai Medical CenterLos AngelesCAUSA
- Cedars‐Sinai Medical CenterSmidt Heart InstituteLos AngelesCAUSA
| | - Jennifer E. Van Eyk
- Department of Biomedical SciencesCedars‐Sinai Medical CenterLos AngelesCAUSA
- Barbara Streisand Women’s Heart CenterCedars‐Sinai Medical CenterLos AngelesCAUSA
- Department of MedicineCedars‐Sinai Medical CenterLos AngelesCAUSA
| | - Keith L. Black
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Vivek K. Gupta
- Department of Molecular SciencesMacquarie UniversitySydneyNSWAustralia
| | - Mehdi Mirzaei
- Department of Clinical MedicineMacquarie UniversitySydneyNSWAustralia
- Department of Molecular SciencesMacquarie UniversitySydneyNSWAustralia
- Australian Proteome Analysis FacilityMacquarie UniversitySydneyNSWAustralia
| | - Yosef Koronyo
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
| | - Maya Koronyo‐Hamaoui
- Department of NeurosurgeryCedars‐Sinai Medical CenterMaxine Dunitz Neurosurgical Research InstituteLos AngelesCAUSA
- Department of Biomedical SciencesCedars‐Sinai Medical CenterLos AngelesCAUSA
| |
Collapse
|
3
|
Wang LY, Fan RF, Yang DB, Zhang D, Wang L. Puerarin reverses cadmium-induced lysosomal dysfunction in primary rat proximal tubular cells via inhibiting Nrf2 pathway. Biochem Pharmacol 2019; 162:132-141. [DOI: 10.1016/j.bcp.2018.10.016] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Accepted: 10/16/2018] [Indexed: 12/31/2022]
|
4
|
Mamais A, Manzoni C, Nazish I, Arber C, Sonustun B, Wray S, Warner TT, Cookson MR, Lewis PA, Bandopadhyay R. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. Brain Res 2018; 1701:75-84. [PMID: 30055128 PMCID: PMC6361106 DOI: 10.1016/j.brainres.2018.07.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 07/04/2018] [Accepted: 07/24/2018] [Indexed: 12/12/2022]
Abstract
LRRK2, the gene encoding the multidomain kinase Leucine-Rich Repeat Kinase 2 (LRRK2), has been linked to familial and sporadic forms of Parkinson's disease (PD), as well as cancer, leprosy and Crohn's disease, establishing it as a target for discovery therapeutics. LRRK2 has been associated with a range of cellular processes, however its physiological and pathological functions remain unclear. The most prevalent LRRK2 mutations in PD have been shown to affect macroautophagy in various cellular models while a role in autophagy signalling has been recapitulated in vivo. Dysregulation of autophagy has been implicated in PD pathology, and this raises the possibility that differential autophagic activity is relevant to disease progression in PD patients carrying LRRK2 mutations. To examine the relevance of LRRK2 to the regulation of macroautophagy in a disease setting we examined the levels of autophagic markers in the basal ganglia of G2019S LRRK2 PD post-mortem tissue, in comparison to pathology-matched idiopathic PD (iPD), using immunoblotting (IB). Significantly lower levels of p62 and LAMP1 were observed in G2019S LRRK2 PD compared to iPD cases. Similarly, an increase in ULK1 was observed in iPD but was not reflected in G2019S LRRK2 PD cases. Furthermore, examination of p62 by immunohistochemistry (IH) recapitulated a distinct signature for G2019S PD. IH of LAMP1, LC3 and ULK1 broadly correlated with the IB results. Our data from a small but pathologically well-characterized cases highlights a divergence of G2019S PD carriers in terms of autophagic response in alpha-synuclein pathology affected brain regions compared to iPD.
Collapse
Affiliation(s)
- Adamantios Mamais
- Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, United Kingdom; Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, NIA, NIH, Building 35, 35 Convent Drive, Bethesda, MD 20892-3707, USA.
| | - Claudia Manzoni
- School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, United Kingdom; Department of Neurodegenerative Diseases, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
| | - Iqra Nazish
- Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, United Kingdom; Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, WC1N 3BG, United Kingdom
| | - Charles Arber
- Department of Neurodegenerative Diseases, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
| | - Berkiye Sonustun
- Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, United Kingdom
| | - Selina Wray
- Department of Neurodegenerative Diseases, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
| | - Thomas T Warner
- Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, United Kingdom; Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, WC1N 3BG, United Kingdom
| | - Mark R Cookson
- Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, NIA, NIH, Building 35, 35 Convent Drive, Bethesda, MD 20892-3707, USA
| | - Patrick A Lewis
- School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, United Kingdom; Department of Neurodegenerative Diseases, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
| | - Rina Bandopadhyay
- Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, United Kingdom; Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, WC1N 3BG, United Kingdom.
| |
Collapse
|